All azoospermic males should be screened for cystic fibrosis mutations before intracytoplasmic sperm injection

Edgar Mocanu; Richard Shattock; David Barton; Melissa Rogers; Ronan Conroy; Orla Sheils; Claire Collins; Cara Martin; Robert Harrison; John O'Leary

doi:10.1016/j.fertnstert.2010.02.029

All azoospermic males should be screened for cystic fibrosis mutations before intracytoplasmic sperm injection

Fertil Steril. 2010 Nov;94(6):2448-50. doi: 10.1016/j.fertnstert.2010.02.029. Epub 2010 Apr 9.

Authors

Edgar Mocanu¹, Richard Shattock, David Barton, Melissa Rogers, Ronan Conroy, Orla Sheils, Claire Collins, Cara Martin, Robert Harrison, John O'Leary

Affiliation

¹ Human Assisted Reproduction Ireland, Rotunda Hospital, and Royal College of Surgeons in Ireland, Dublin, Ireland. emocanu@rcsi.ie

PMID: 20381036
DOI: 10.1016/j.fertnstert.2010.02.029

Abstract

We assessed the frequency of CFTR mutations in groups with varying degrees of sub-fertility and compared these groups to a fertile male group with proven paternity. Screening for CFTR mutations should be routine for all azoospermic males, irrespective of obstructive or non-obstructive etiology, prior to proposing ICSI treatment. CFTR testing has no value in the investigation of non-azoospermic infertile males.

Publication types

Evaluation Study

MeSH terms

Azoospermia / diagnosis*
Azoospermia / genetics*
Azoospermia / therapy
Case-Control Studies
Cystic Fibrosis / diagnosis
Cystic Fibrosis / genetics*
Cystic Fibrosis Transmembrane Conductance Regulator / genetics*
DNA Mutational Analysis
Gene Frequency
Genetic Carrier Screening
Genetic Testing / methods
Humans
Infertility, Male / etiology
Infertility, Male / genetics
Infertility, Male / therapy
Male
Mutation
Predictive Value of Tests
Prognosis
Sperm Injections, Intracytoplasmic*

Substances

Cystic Fibrosis Transmembrane Conductance Regulator